ProCE Banner Series

CAR T-Cell Therapy in Multiple Myeloma: Current Evidence and Guidance to Support Optimal Integration into Care

Join this interactive live webinar discussing the critical role of advanced practice providers in enhancing the care of patients with multiple myeloma undergoing CAR T-cell therapy. Bring questions for our expert panel of nurse and physician associate faculty.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced-degree nurses who care for patients with multiple myeloma who are potential candidates for CAR T-cell therapy.

All Events

CAR T-Cell Therapy in Multiple Myeloma: Current Evidence and Guidance to Support Optimal Integration into Care

Upcoming Events

January

09

2025

6:00 PM - 8:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio

ProCE Banner Faculty
Tiffany Richards, PhD, ANP-BC, AOCNP

Nurse Practitioner
Department of Lymphoma/Myeloma
MD Anderson Cancer Center
Houston, Texas

 

ProCE Banner Faculty
Danielle Roberts, PA-C

Associate Chief of Education for APPs
Director, Hematology/Oncology APP Fellowship
Winship Cancer Institute at Emory University
Atlanta, Georgia

Topics

Multiple Myeloma

Hematologic Malignancies

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with CAR-T. 

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced-degree nurses who care for patients with multiple myeloma who are potential candidates for CAR T-cell therapy. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Differentiate the rationale for and mechanisms of CAR T-cell therapies vs other anticancer therapies in multiple myeloma
  • Evaluate current and emerging efficacy and safety evidence for the use of CAR T-cell therapies in multiple myeloma
  • Initiate discussions with patients on the requirements of CAR T-cell therapy, including referral to specialized treatment centers, patient care coordination, and pre/post-treatment support
  • Identify toxicities associated with CAR T-cell therapies and their recommended management strategies

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by educational grants from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC and Legend Biotech USA, Inc.